Monte Rosa Therapeutics to Present Late-breaking Preclinical Data on Targeting GSPT1 for Myc-driven Cancers at AACR-NCI-EORTC Virtual International Conference

Rhea-AI Summary

Monte Rosa Therapeutics (NASDAQ: GLUE) announced that its preclinical data for GSPT1-directed molecular glue degrader targeting Myc-driven breast cancer will be presented at the AACR-NCI-EORTC Virtual International Conference from Oct. 7-10. The study, titled "Identification of GSPT1-mediated molecular glue degraders for the treatment of Myc-driven cancers", will be showcased as a late-breaking poster by Gerald Gavory, Ph.D., poster number LBA004. This presentation highlights the company’s innovative approach to developing precision medicines.

Positive

• Selection of GSPT1-directed molecular glue degrader data for late-breaking poster presentation indicates recognition in the scientific community.
• Focus on Myc-driven breast cancer aligns with significant market need for targeted therapies.

Negative

• None.

BOSTON, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE), a biotechnology company developing novel molecular glue precision medicines, today announced that preclinical data for the company’s GSPT1-directed molecular glue degrader targeting Myc-driven breast cancer has been selected for a late-breaking poster presentation at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics from Oct. 7-10.

Presentation Details:
Title: Identification of GSPT1-mediated molecular glue degraders for the treatment of Myc-driven cancers
Presenter: Gerald Gavory, Ph.D.
Poster Number: LBA004
Date/Time: Available on-demand throughout conference

About Monte Rosa
Monte Rosa Therapeutics is a biotechnology company developing a portfolio of novel molecular glue degrader precision medicines. These medicines are designed to employ the body’s natural mechanisms to selectively eliminate therapeutically relevant proteins. The company has developed a proprietary protein degradation platform, called QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates), that enables it to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates that are designed to eliminate therapeutically relevant proteins in a highly selective manner. The company’s drug discovery platform combines diverse and proprietary chemical libraries of small molecule protein degraders with in-house proteomics, structural biology, AI/machine learning-based target selection and computational chemistry capabilities to predict and obtain protein degradation profiles. Monte Rosa was launched from founding investor Versant Ventures’ Ridgeline Discovery Engine and is headquartered in Boston, Mass., with research operations in both Boston and Basel, Switzerland. 

Contacts:

Investors
Michael Morabito, Solebury Trout
ir@monterosatx.com

Media
Dan Budwick, 1AB
dan@1abmedia.com

FAQ

What is the significance of Monte Rosa Therapeutics' poster presentation at the AACR-NCI-EORTC conference?

The poster presentation highlights important preclinical data on GSPT1-directed molecular glue degraders, showcasing innovative cancer treatment approaches.

When will the poster presentation for Monte Rosa's GSPT1-directed molecular glue degrader take place?

The poster will be available on-demand throughout the AACR-NCI-EORTC Virtual International Conference from October 7-10.

Who is presenting Monte Rosa's research at the conference?

Gerald Gavory, Ph.D., will present the research on GSPT1-mediated molecular glue degraders.

What type of cancer is the focus of the GSPT1-directed molecular glue degrader?

The GSPT1-directed molecular glue degrader specifically targets Myc-driven breast cancer.

How does Monte Rosa's QuEEN™ platform contribute to drug discovery?

The QuEEN™ platform enables rapid identification of protein targets and molecular glue degraders, enhancing the development of precision medicines.